
Data Driven Studies: Fusion is Axiom’s proprietary, easy-to-use and cost-effective eClinical solution that is focused on small to medium sized device, pharma, and biotech companies.
Over 15 fully integrated modules that connect seamlessly in one unified platform – accessible with a single sign-on.
Axiom offers the following training material(s) available for the REGENXBIO – ATMOSPHERE study:

REGENXBIO is seeking to improve lives through the curative potential of gene therapy. Our NAV® Technology Platform has ushered in a new era of gene therapy innovation.
ATMOSTPHERE is a multi-center, randomized, active-controlled trial to evaluate the efficacy and safety of RGX-314 Gene Therapy in patients with nAMD.